SCHEMBL7018158

SCHEMBL7018158

CCN(c1cccc([N+](=O)[O-])c1)c1nccc(-n2cnc3ccc(NC(=O)c4ccccc4)cc32)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 1/20 0.46
▸ ORAI1 Q96D31 1/20 0.44
▸ ATM Q13315 2/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ IRAK4 Q9NWZ3 2/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ THRB P10828 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7016618 0.95 NPC1 (0.47) LCKORAI1ATMNPC1RAB9A
SCHEMBL7020638 0.74 MKNK2 (0.52) LCKORAI1NPC1RAB9AMKNK1
SCHEMBL7020932 0.73 MKNK2 (0.51) LCKORAI1NPC1RAB9AMKNK1
SCHEMBL7025397 0.71 MAP3K14 (0.49) LCKMKNK1MKNK2MAPT
SCHEMBL7017821 0.70 LCK (0.56) LCKMKNK1MKNK2
SCHEMBL7024895 0.70 LCK (0.68) LCKMKNK1MKNK2
SCHEMBL7567370 0.70 MAP3K14 (0.46) LCKMKNK1MKNK2HPGD
SCHEMBL2294002 0.67 MEN1 (0.50) ATMNPC1RAB9AL3MBTL1IRAK4
SCHEMBL7552289 0.67 NPC1 (0.56) LCKORAI1NPC1RAB9AMKNK1
SCHEMBL7022622 0.67 JAK2 (0.63) LCKMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 — — EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 — — US disclosed
Send feedback